O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648 - Ian Chau, et al
O-4: Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas) - Per Pfeiffer, et al
SO-7: Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial - Yelena Janjigian, et al
SO-8: Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR) - Hisato Kawakami, et al
